What is MCAS?
Mast cells are immune cells that release chemicals like histamine to fight infection and respond to allergens. In Mast Cell Activation Syndrome (MCAS), mast cells release their chemicals too easily or too often.
This can cause a wide range of allergy-like symptoms, including:
-
Flushing, itching, hives
-
Wheezing or chest tightness
-
Abdominal pain, diarrhoea, nausea
-
Drop in blood pressure, dizziness, “anaphylaxis-like” episodes
-
Fatigue and brain fog
Unlike systemic mastocytosis (see below), in MCAS the number of mast cells is normal — they are just overactive.
What is Mastocytosis?
Mastocytosis is a rare disease where the body makes too many mast cells, which then build up in the skin, bone marrow, or other organs.
-
Symptoms can include skin spots (urticaria pigmentosa), itching, flushing, abdominal pain, or even severe allergic reactions.
-
It is usually diagnosed with a bone marrow biopsy, persistently raised tryptase levels, and sometimes genetic testing (KIT mutations).
-
It is much rarer than MCAS — affecting perhaps 1 in 10,000–20,000 people.
-
Unlike MCAS, it is well-recognised by the NHS and has clearer diagnostic criteria.
👉 Key difference:
-
Mastocytosis = too many mast cells (rare, testable, well-defined).
-
MCAS = mast cells behaving abnormally (more common, debated, less defined).
Why is MCAS controversial?
The problem is not whether patients are unwell — their symptoms are very real. The debate is about diagnosis:
-
No gold-standard test: mast cell markers (tryptase, histamine, prostaglandins) fluctuate, so results may be normal between flares.
-
Overlapping symptoms: MCAS can look like asthma, ABPA, IBS, coeliac disease, POTS, autoimmune disease, or anxiety.
-
Different acceptance worldwide: in the US and Germany, MCAS is more widely recognised; in the NHS, it is rarely diagnosed formally.
-
Risk of mislabelling: some doctors fear that calling everything “MCAS” could delay other correct diagnoses.
MCAS is still being debated and developed
It is important to understand that MCAS is a work in progress:
-
International allergy bodies (AAAAI, EAACI, WAO) are actively developing clearer diagnostic criteria.
-
Research is ongoing into more reliable biomarkers (tryptase, histamine metabolites, prostaglandin D2) and genetic links.
-
Different schools of thought: some specialists see MCAS as common and under-recognised, others worry about overdiagnosis.
-
NHS position: the UK is cautious, waiting for stronger evidence before making MCAS a routine diagnosis.
-
Future direction: most experts expect MCAS will eventually be better defined, possibly with subtypes (allergic, autoimmune, idiopathic), clearer tests, and tailored treatments such as biologics.
👉 For now, patients should know: MCAS is real for many, but it remains under scientific development, which is why experiences differ depending on which doctor you see.
MCAS and Aspergillosis – is there a link?
There is no proven direct link between MCAS and aspergillosis, but there are overlaps:
-
In Allergic Bronchopulmonary Aspergillosis (ABPA), mast cells release histamine and other mediators in response to Aspergillus spores — very similar to MCAS.
-
In Chronic Pulmonary Aspergillosis (CPA), mast cells are found in lung tissue, but their role isn’t well understood.
-
Both conditions can cause wheeze, fatigue, breathlessness, and allergic-type symptoms, though for different reasons.
Some specialists suggest patients with very sensitive mast cells may react more strongly to fungal exposure. Conversely, chronic fungal inflammation may “prime” mast cells to overreact.
Why careful diagnosis matters
It’s possible to see a patient who looks like they have MCAS but actually responds to another diagnosis and treatment:
-
Asthma/ABPA → inhaled steroids, biologics, antifungals
-
POTS → fluids, salt, and blood-pressure medicines
-
Coeliac disease/IBS → dietary management
-
Autoimmune disease → immunosuppressants
This is why doctors are cautious: assuming MCAS too quickly could delay the right treatment.
What the future may hold
-
Better definitions: international allergy societies are working on clearer criteria to separate MCAS from other conditions.
-
More research: scientists are studying mast cell biology, genetics, and biomarkers.
-
Improved treatments: antihistamines, mast cell stabilisers, and leukotriene blockers are already used; biologics (like omalizumab or dupilumab) are being studied.
-
Greater NHS recognition: if stronger evidence emerges, MCAS is more likely to be formally recognised in the UK.
Differences between countries
-
In the US and Germany, MCAS is more widely recognised, and patients may find it easier to get the label and access to mast-cell–targeted treatments (antihistamines, leukotriene blockers, mast cell stabilisers, biologics in some cases).
-
In the UK/NHS, doctors are much more cautious and rarely use “MCAS” as a formal diagnosis, even when symptoms fit. Treatment is often offered pragmatically, without the label.
-
Does this mean outcomes are better in the US/Germany?
-
There is no strong evidence yet that patients in those countries do better long-term just because they get the MCAS diagnosis.
-
What’s different is mostly access to recognition and treatment, not proven improvements in quality of life compared with the UK.
-
Ongoing research is needed to show whether having the diagnosis itself improves patient outcomes.
-
Key take-home message for aspergillosis patients
-
MCAS is real for patients, but controversial in medicine. The debate is about safe diagnosis, not whether people are genuinely unwell.
-
Mastocytosis is different: it is rare, clearly defined, and testable — whereas MCAS is more common but less well recognised.
-
Aspergillosis overlaps with MCAS because both involve mast cell activity and histamine release, especially in ABPA.
-
Different countries handle it differently: US/Germany diagnose it more often, the UK is cautious — but there is no clear proof yet that outcomes are better where it’s recognised more widely.
-
The most important thing is to get a careful, accurate diagnosis, so the right treatment can be given — whether that turns out to be MCAS, asthma, ABPA, or another condition.
👉 In short: Mastocytosis is rare and well-defined. MCAS is more common but debated. Both share features with aspergillosis, especially ABPA. MCAS is still being researched and developed, and while some countries recognise it more widely, there’s no solid evidence yet that this leads to better outcomes than the cautious UK approach.
Latest News posts
News archive